2025-10-08T15:08:46+00:00 2024-12-31 135381590 BDO USA ONE INTERNATIONAL PLACE BOSTON MA 02110 990 2024-01-01 352711268 INTREPID ALLIANCE INC CO BROWNE CONSULTING GROUP INTR 7817572081 ONE BROADWAY 14TH FL CAMBRIDGE MA 01242 JAMES BERGIN TREASURER 6167747000 2025-10-08 true JAKE COOK P01240455 6174220700 2025-10-07 2024 2025-03-06 01:10:19Z JAMES ANDERSON ONE BROADWAY 14TH FL CAMBRIDGE MA 01242 2245192 false X INTREPIDALLIANCE.ORG X 2021 DE PROMOTE THE COMMON BUSINESS INTEREST OF ITS MEMBERS OF ADVANCING GLOBAL HEALTH SECURITY THROUGH ANTIVIRAL PANDEMIC PREPAREDNESS EFFORTS. 8 8 0 21 0 0 1500000 2250000 0 -4808 1500000 2245192 0 0 319996 300000 0 0 983248 1630908 1303244 1930908 196756 314284 1913894 2256819 98008 126649 1815886 2130170 THE PRIMARY PURPOSE OF THE CORPORATION IS TO PROMOTE THE COMMON BUSINESS INTEREST OF ITS MEMBERS OF ADVANCING GLOBAL HEALTH SECURITY THROUGH PANDEMIC PREPAREDNESS EFFORTS. THE CORPORATION WILL PURSUE THIS PURPOSE BY PROMOTING THE DEVELOPMENT OF NEW TREATMENTS FOR EMERGING VIRAL PANDEMIC PATHOGENS THROUGH COORDINATED EARLY SCIENCE, POLICY AND ADVOCACY, STAKEHOLDER ENGAGEMENT THAT FACILITATES INFORMATION SHARING, AND ADVANCING AND CREATING EFFICIENCIES IN EARLY RESEARCH AND DEVELOPMENT AMONG ITS MEMBERS AND OTHERS IN THE ANTIVIRAL R&D ECOSYSTEM. IN THIS WAY THE CORPORATION AIMS TO SUPPORT THE 100 DAY MISSION, AN INTERNATIONAL EFFORT BY THE INTERNATIONAL PANDEMIC PREPAREDNESS SECRETARIAT (IPPS.ORG) "TO PREPARE AS MUCH AS POSSIBLE SO THAT WITHIN THE FIRST 100 DAYS A PANDEMIC THREAT IS IDENTIFIED AN INITIAL REGIMEN OF THERAPEUTICS" CAN BE MADE AVAILABLE BY RESEARCH ENTERPRISES THAT ARE SAFE, EFFECTIVE AND AFFORDABLE. false false BEYOND COVID-19, GLOBALIZATION, URBAN EXPANSION, AND EXPLOITATION OF NATURAL HABITATS SUGGEST HUMANITY WILL FACE NEW FORMS OF RESPIRATORY AND OTHER PATHOGENS THAT HOLD THE POTENTIAL TO CAUSE PANDEMICS. ORALLY AVAILABLE SMALL-MOLECULE ANTIVIRAL DRUGS FOR RAPID MOBILIZATION AND DISTRIBUTION ARE A CRITICAL TOOL TO PROTECT SOCIETIES FROM ANOTHER VIRAL PANDEMIC. UNLIKE SOME VACCINES AND ANTIBODIES, ANTIVIRAL THERAPIES MIGHT BE LESS PRONE TO THE IMPACT OF VIRUS GENETIC EVOLUTION, MAY BE EFFECTIVE AGAINST A BROAD RANGE OF VIRUSES, AND CAN CHANGE THE COURSE OF DISEASE EVEN AFTER INFECTION. MOST SMALL MOLECULE ANTIVIRALS CAN BE PRODUCED RAPIDLY AND COST-EFFECTIVELY AT A GLOBAL SCALE IN EXISTING FACILITIES, BUT THEY REQUIRE YEARS TO DISCOVER AND DEVELOP, SO IT IS CRITICAL TO PROMOTE AND SUPPORT RESEARCH, ADVOCACY, AND SCIENTIFIC INFORMATION SHARING ACROSS THE ACADEMIC BIOTECH AND PHARMACEUTICAL INDUSTRY. IN ORDER TO CREATE EFFICIENCIES IN THE R&D ECOSYSTEM, THE CORPORATION WILL COLLABORATE WITH PARTNERS IN OTHER SECTORS AND ITS MEMBERS IN EXPLORING REDUNDANCIES AND OPPORTUNITIES TO COLLABORATE FOR THE BENEFIT OF HUMANITY SUCH AS SHARING NEW RESEARCH FINDINGS, CREATING GUIDELINES SUCH AS TARGET PRODUCT PROFILES, BENCHMARKING GLOBAL R&D EFFORTS AGAINST PATHOGENS OF PANDEMIC CONCERN AND CREATING A LISTING OF PROMISING LEAD PRODUCT CANDIDATES BY RESEARCHERS GLOBALLY. WE HOPE TO ACCELERATE THE COLLECTIVE UNDERSTANDING OF VIRAL TARGETS AND INCREASE THE LIKELIHOOD OF THE R&D ECOSYSTEM IN IDENTIFYING PROMISING LEADS. THE CORPORATION INTENDS TO FACILITATE FURTHER SCIENTIFIC INFORMATION SHARING BY DEVELOPING WHITE PAPERS ON RELEVANT TOPICS, PERFORMING A LANDSCAPE AND NEEDS ASSESSMENT ACROSS PUBLIC AND PRIVATE ANTIVIRAL RESEARCH SECTORS, AND PROVIDING KNOWLEDGE-SHARING OPPORTUNITIES THROUGH ORGANIZING MEETINGS AND SEMINARS. THE CORPORATION ALSO ORGANIZED AND PRODUCED A GLOBAL SUMMIT ON ANTIVIRAL PREPAREDNESS FOR 100 STAKEHOLDERS, PUBLISHED AND DISSEMINATED THE ANTIVIRAL SUMMIT PROCEEDINGS AND RECOMMENDATIONS, RESEARCHED, ANALYZED AND AUTHORED THE ANTIVIRAL CLINICAL DEVELOPMENT LANDSCAPE FOR PUBLICATION IN JANUARY 2024 AND DEVELOPED A TARGET COMPOUND PROFILE TO GUIDE ACADEMIC, BIOTECH, PHARMA AND GOVERNMENT DRUG DEVELOPERS IN THEIR R&D FOR ANTIVIRALS. 0 false false false false true false false false false false false false false false false false false false false false true false false false false false false false false true false false false false false false false false false false false false false false false false false false false false true 16 0 true 0 false false false false false false false false X 8 8 false false true false true true false true true false false false true true true true false false true false false false X X BROWNE CONSULTING GROUP 7817572081 ONE BROADWAY 14TH FL CAMBRIDGE MA 01242 JAMES ANDERSON PRESIDENT 1.0 X X 0 0 0 LYDIA OGDEN SECRETARY 1.0 X X 0 0 0 DEREK WALLACE DIRECTOR (AS OF 11/2024) 1.0 X 0 0 0 KENNETH BRADLEY DIRECTOR 1.0 X 0 0 0 KUMAR SINGH SAIKATENDU DIRECTOR (THRU 08/2024) 1.0 X 0 0 0 MARGARET CHU-MOYER DIRECTOR 1.0 X 0 0 0 MICHELLE PARKS DIRECTOR 1.0 X 0 0 0 SUJATA VAIDYANATHAN DIRECTOR 1.0 X 0 0 0 TOMAS CIHLAR DIRECTOR 1.0 X 0 0 0 JAMES BERGIN TREASURER 1.0 X 0 0 0 NINA HILL SECRETARIAT 40.0 X 298844 0 0 298844 0 0 1 false true false HILL SCIENTIFIC AND PUBLIC AFFAIRS LLC 420 EAST 72ND STREET NEW YORK NY 10021 SECRETARIAT 298844 DRAGHIA HEALTHCARE CONSULTING LLC 656 HEATHERWOOD ROAD BRYN MAWR PA 19010 CONSULTING 230892 MOUNTAINEER BIO LLC 2212 MEADOWCREEK DRIVE DURHAM NC 27705 R&D CONSULTANT 214610 JOHN C POTTAGE JR 107 DEVON ROAD PAOLI PA 19301 R&D CONSULTANT 183170 COVINGTON AND BURLING PO BOX 3225 CAROL STREAM IL 60132 LEGAL 149305 7 0 MEMBERSHIP DUES 621500 2250000 2250000 0 0 0 0 2250000 0 0 0 0 0 FOREIGN CURRENCY EXCHANGE GAIN/LOSS 900099 -4808 -4808 0 0 0 0 -4808 2245192 2245192 0 0 298844 1156 190327 60660 0 116793 86001 75353 RESEARCH & DEVELOPMENT 1101774 0 1930908 1787403 2130812 0 0 126491 126007 0 0 0 0 0 0 0 1913894 2256819 98008 126649 0 0 0 98008 126649 X 1815886 2130170 1815886 2130170 1913894 2256819 314284 0 X false false false false true false Europe (Including Iceland and Greenland) 0 0 Program Services MEMBERSHIP DUES 750000 0 0 0 0 0 0 750000 0 750000 false false false false false false Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual X X X false false false NINA HILL SECRETARIAT 298844 0 0 0 0 0 0 0 0 0 298844 0 0 0 Form 990, Part VI, Line 4 Significant changes to organizational documents EFFECTIVE NOVEMBER 8, 2024, THE ORGANIZATION AMENDED ITS BYLAWS TO INCLUDE ON THE BOARD, FROM TIME-TO-TIME, ONE OR MORE ORGANIZATIONS THAT REPRESENT THE BUSINESS INTERESTS OF ORGANIZATIONS OPERATING IN INDUSTRIES ADJACENT TO THOSE OF THE CORPORATION'S MEMBERS AS AN INDUSTRY AFFILIATE GROUP. THESE MEMBERS SHALL NOT EXCEED THE NUMBER OF BIOPHARMACEUTICAL MEMBERS. Form 990, Part VI, Line 6 Classes of members or stockholders THE CORPORATION HAS ONE CLASS OF MEMBERSHIP. AN ORGANIZATION IS ELIGIBLE FOR MEMBERSHIP IF IT IS A BIOPHARMACEUTICAL COMPANY OR INDUSTRY ADJACENT COMPANY ENGAGED IN THE PRODUCTION AND DEVELOPMENT OF PHARMACEUTICAL PRODUCTS AND IS NOT OTHERWISE PROHIBITED BY TREATY, LAW OR REGULATION FROM ABIDING BY THE TERMS OF THE CORPORATION'S BYLAWS AND MEMBERSHIP AGREEMENT. Form 990, Part VI, Line 7a Members or stockholders electing members of governing body THE MEMBERS HAVE THE RIGHT TO VOTE ON THE ADMISSION OF NEW MEMBERS, THE APPOINTMENT OR ELECTION OF DIRECTORS, THE REMOVAL OF DIRECTORS AND THE ADOPTION, AMENDMENT, CHANGE OR REPEAL OF THE ORGANIZATION'S ORGANIZING DOCUMENTS. Form 990, Part VI, Line 11b Review of form 990 by governing body THE ORGANIZATION'S FORM 990 IS PROVIDED TO THE BOARD FOR REVIEW PRIOR TO FILING. Form 990, Part VI, Line 12c Conflict of interest policy THE CORPORATION'S BOARD HAS ADOPTED A CONFLICT OF INTEREST POLICY THAT REQUIRES OFFICERS AND DIRECTORS OF THE CORPORATION TO, ON AN ANNUAL BASIS, SIGN A STATEMENT AFFIRMING THAT THEY HAVE RECEIVED A COPY OF THE POLICY, HAVE READ AND UNDERSTAND THE POLICY, AND HAVE AGREED TO COMPLY WITH THE POLICY. Form 990, Part VI, Line 15a Process to establish compensation of top management official 990'S WERE REVIEWED FOR COMPARABLE FEES FOR CONSULTANTS WHO SERVE AS CEO, EXECUTIVE DIRECTOR OR SECRETARIAT; CONSULTANT HOURLY RATES WERE ALSO COMPARED TO HOURLY RATES OF COMPARABLE CONSULTANTS IN LIFE SCIENCES. THE CHAIR AND TREASURER REVIEWED AND APPROVED THE HOURLY RATE AND BASED UPON THE NUMBER OF HOURS SPENT WORKING IN 2022 AND BASED UPON THE STRATEGIC WORK PLAN FOR 2024 A TARGET RANGE OF HOURS WAS ARRIVED AT. THE RATE WAS APPROVED BY THE FINANCE COMMITTEE AND BY THE BOARD. A WRITTEN CONTRACT WAS EXECUTED IN 2022. Form 990, Part VI, Line 19 Required documents available to the public THE CORPORATION MAKES THESE DOCUMENTS AVAILABLE UPON WRITTEN REQUEST TO THE SECRETARY.